Lv11
50 积分 2024-06-20 加入
Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
4天前
已完结
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors
16天前
已完结
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
21天前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
1个月前
已完结
Induction of TRPC6 Channel in Acquired Forms of Proteinuric Kidney Disease
1个月前
已完结
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
1个月前
已完结
RAF kinase dimerization: implications for drug discovery and clinical outcomes
1个月前
已完结
Cutaneous toxicities of RAF inhibitors
1个月前
已完结
Advances in the management of localized bladder cancers
1个月前
已完结
The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers
3个月前
已完结
皖公网安备34019202002308
